/HTFL
HTFL Stock - Heartflow, Inc. Common Stock
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$30.51+6.49%
+$1.86 (+6.49%) • Dec 19
48
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.35
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).84
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+17.2%upside
Target: $35.76
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HTFL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$30.20 – $30.82
TARGET (TP)$35.75
STOP LOSS$28.07
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta6.44
52W High$41.22
52W Low$25.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $125.81M | $87.17M |
| Gross Profit | $94.45M | $58.05M |
| Gross Margin | 75.1% | 66.6% |
| Operating Income | $-61,222,000 | $-72,914,000 |
| Net Income | $-96,426,000 | $-95,655,000 |
| Net Margin | -76.6% | -109.7% |
| EPS | $-1.49 | $-1.94 |
Company Overview
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company's platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. The company was founded in 2007 and is headquartered in Mountain View, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
67%
Hold / Neutral
1
33%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish1 Neutral/Bearish
Price Targets
$36
Average Target
↑ 17.3% Upside
Now
$35
Low
$36
Average
$38
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 2nd 2025 | JP Morgan | Initiation | Overweight | $36 |
| September 2nd 2025 | Piper Sandler | Initiation | Overweight | $38 |
| September 2nd 2025 | Stifel | Initiation | Buy | $35 |
| September 2nd 2025 | Canaccord Genuity | Initiation | Buy | $35 |
| September 2nd 2025 | Morgan Stanley | Initiation | Equal Weight | $35 |
Earnings History & Surprises
HTFLBeat Rate
0%
Last 2 quarters
Avg Surprise
-332.5%
EPS vs Estimate
Beats / Misses
0/2
Last 12 quarters
Latest EPS
$-0.27
Q4 2025
EPS Surprise History
Q3 25
-630.0%
$-1.46vs$-0.20
Q4 25
-35.0%
$-0.27vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 11, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.20 | $-0.27 | -35.0% | ✗ MISS |
Q3 2025 | Sep 19, 2025 | $-0.20 | $-1.46 | -630.0% | ✗ MISS |
Latest News
Heartflow Announces American College Of Cardiology, American Heart Association Published New Scientific Statement Supporting Its Coronary Plaque Analysis
📈 PositiveBenzinga•Dec 18, 2025, 09:09 PM
Heartflow FFRCT Analysis Shows Prognostic Power And Significant Cost Savings In New Study Of Over 90,000 Coronary Artery Disease Patients
📈 PositiveBenzinga•Dec 11, 2025, 09:08 AM
Canaccord Genuity Maintains Buy on HeartFlow, Raises Price Target to $40
📈 PositiveBenzinga•Nov 13, 2025, 08:56 PM•Also:
JP Morgan Maintains Overweight on HeartFlow, Raises Price Target to $40
📈 PositiveBenzinga•Nov 13, 2025, 06:44 PM
Stifel Maintains Buy on HeartFlow, Raises Price Target to $40
📈 PositiveBenzinga•Nov 13, 2025, 04:13 PM•Also:
Heartflow shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 13, 2025, 03:35 PM
HeartFlow Sees FY2025 Sales $173.000M-$173.500M vs $165.900M Est
📈 PositiveBenzinga•Nov 12, 2025, 10:59 PM
HeartFlow Q3 Adj. EPS $(0.27) Misses $(0.22) Estimate, Sales $46.276M Beat $41.960M Estimate
➖ NeutralBenzinga•Nov 12, 2025, 09:05 PM
Reported Sunday, Heartflow Plaque Staging Proven At AHA 2025 To Predict Major Cardiovascular Events With Fivefold Greater Risk Accuracy
📈 PositiveBenzinga•Nov 10, 2025, 08:01 AM
Heartflow To Present New Late-Breaking Data Highlighting Clinical And Economic Value Of Heartflow Plaque Analysis At AHA Scientific Sessions 2025
📈 PositiveBenzinga•Nov 3, 2025, 01:05 PM
HTFL stock has given up its prior gain. Heartflow shares were trading higher after the company announced it received FDA 501(k) clearance for its Heartflow Plaque Analysis algorithm.
➖ NeutralBenzinga•Sep 22, 2025, 09:06 PM
Heartflow shares are trading higher after the company announced it received FDA 501(k) clearance for its Heartflow Plaque Analysis algorithm.
📈 PositiveBenzinga•Sep 22, 2025, 08:36 PM
Heartflow Receives FDA 510(k) Clearance For Its Next Gen Heartflow Plaque Analysis Algorithm
📈 PositiveBenzinga•Sep 22, 2025, 08:08 PM
Canaccord Genuity Maintains Buy on HeartFlow, Raises Price Target to $39
📈 PositiveBenzinga•Sep 22, 2025, 12:09 PM•Also:
Stifel Initiates Coverage On HeartFlow with Buy Rating, Announces Price Target of $35
📈 PositiveBenzinga•Sep 2, 2025, 12:31 PM•Also:
Canaccord Genuity Initiates Coverage On HeartFlow with Buy Rating, Announces Price Target of $35
📈 PositiveBenzinga•Sep 2, 2025, 11:38 AM•Also:
Piper Sandler Initiates Coverage On HeartFlow with Overweight Rating, Announces Price Target of $38
📈 PositiveBenzinga•Sep 2, 2025, 10:16 AM
JP Morgan Initiates Coverage On HeartFlow with Overweight Rating, Announces Price Target of $36
📈 PositiveBenzinga•Sep 2, 2025, 10:15 AM•Also:
Bain Capital backed Heartflow surges on public debut
📈 PositiveSeeking Alpha•Aug 8, 2025, 05:39 PM
Frequently Asked Questions about HTFL
What is HTFL's current stock price?
Heartflow, Inc. Common Stock (HTFL) is currently trading at $30.51 per share. The stock has moved +6.49% today.
What is the analyst price target for HTFL?
The average analyst price target for HTFL is $35.75, based on 1 analyst.
What sector is Heartflow, Inc. Common Stock in?
Heartflow, Inc. Common Stock operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is HTFL's market cap?
Heartflow, Inc. Common Stock has a market capitalization of $2.60 billion, making it a mid-cap company.
Does HTFL pay dividends?
No, Heartflow, Inc. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATEC
Alphatec Holdings, Inc.
$20.01
Mkt Cap: $3.0B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
LIVN
LivaNova PLC
$62.82
Mkt Cap: $3.4B
PRGO
Perrigo Company plc
$13.23
Mkt Cap: $1.8B
PRVA
Privia Health Group, Inc.
$23.64
Mkt Cap: $2.9B
SGRY
Surgery Partners, Inc.
$15.70
Mkt Cap: $2.0B
TARS
Tarsus Pharmaceuticals, Inc.
$81.40
Mkt Cap: $3.5B
TVTX
Travere Therapeutics, Inc.
$34.51
Mkt Cap: $3.1B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to HTFL for comparison